New liposome chemo combo for first-line pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had chemotherapy for cancer that has spread to other parts of the body.
- You are in good enough physical shape to be up and around (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- You have at least one tumor that can be measured on a scan.
- You do not have cancer that started from a rare type of pancreatic cell.
- You do not have serious heart problems like recent heart attack or uncontrolled irregular heartbeat.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for people with pancreatic cancer that has not spread to the brain. It aims to see if this combination works better than standard treatments.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Hear when a new First-line Treatment of Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.